$HUTCHMED(00013)$ delivered a

PSG2010

$HUTCHMED(00013)$ delivered a strong performance in fiscal year 2024, exceeding expectations, driven by the robust international sales growth of fruquintinib.

Looking ahead, we are highly confident in HUTCHMED’s 2025 oncology business target of $350M–$450M, with overall portfolio sales expected to grow 35% YoY in FY2025. Fundamentals remain solid—maintaining a buy rating.

I'll wait for stabilization before adding 10,000 more shares, holding long-term for bigger gains!

Winning Trades

Share your positions with us! This is a column where you can find the winning trades of our fellow tigers. There probably are a few potential opportunities that you may have overlooked.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":415801921802584,"tweetId":"415801921802584","gmtCreate":1742542844307,"gmtModify":1742546237181,"author":{"id":3479274775305388,"idStr":"3479274775305388","authorId":3479274775305388,"authorIdStr":"3479274775305388","name":"PSG2010","avatar":"https://static.tigerbbs.com/7b0d9918c0ae3b5288d953af85e09579","vip":8,"userType":8,"introduction":"运营账号","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":71,"starInvestorFlag":false},"themes":[{"themeId":"7516f9ef7e8042739b8597466da26fe7","categoryId":"7cf744760f454845a1870a05ea4e151d","name":"Winning Trades","type":0,"rnLink":"https://laohu8.com/RN?name=RNTheme&page=/theme/detail&rndata={\"themeId\":7516f9ef7e8042739b8597466da26fe7}&rnconfig={\"headerBarHidden\": true}","description":"Share your positions with us! This is a column where you can find the winning trades of our fellow tigers. There probably are a few potential opportunities that you may have overlooked.","image":"https://community-static.tradeup.com/news/14c89d9656aedb9a4698e7996c575947"}],"images":[{"img":"https://community-static.tradeup.com/news/870a818fdd4357eff5b69504e8b2d463","width":"767","height":"1280"}],"coverImages":[{"img":"https://community-static.tradeup.com/news/870a818fdd4357eff5b69504e8b2d463","width":"767","height":"1280"}],"html":"<html><head></head><body> <a data-mention-id=\"00013\" class=\"teditor-mention\" data-mention-name=\"HUTCHMED\" href=\"https://ttm.financial/S/00013\">$HUTCHMED(00013)$</a> delivered a strong performance in fiscal year 2024, exceeding expectations, driven by the robust international sales growth of fruquintinib. Looking ahead, we are highly confident in HUTCHMED’s 2025 oncology business target of $350M–$450M, with overall portfolio sales expected to grow 35% YoY in FY2025. Fundamentals remain solid—maintaining a buy rating. I'll wait for stabilization before adding 10,000 more shares, holding long-term for bigger gains!<img src=\"https://community-static.tradeup.com/news/870a818fdd4357eff5b69504e8b2d463\" tg-width=\"767\" tg-height=\"1280\"></body></html>","htmlText":"<html><head></head><body> <a data-mention-id=\"00013\" class=\"teditor-mention\" data-mention-name=\"HUTCHMED\" href=\"https://ttm.financial/S/00013\">$HUTCHMED(00013)$</a> delivered a strong performance in fiscal year 2024, exceeding expectations, driven by the robust international sales growth of fruquintinib. Looking ahead, we are highly confident in HUTCHMED’s 2025 oncology business target of $350M–$450M, with overall portfolio sales expected to grow 35% YoY in FY2025. Fundamentals remain solid—maintaining a buy rating. I'll wait for stabilization before adding 10,000 more shares, holding long-term for bigger gains!<img src=\"https://community-static.tradeup.com/news/870a818fdd4357eff5b69504e8b2d463\" tg-width=\"767\" tg-height=\"1280\"></body></html>","text":"$HUTCHMED(00013)$ delivered a strong performance in fiscal year 2024, exceeding expectations, driven by the robust international sales growth of fruquintinib. Looking ahead, we are highly confident in HUTCHMED’s 2025 oncology business target of $350M–$450M, with overall portfolio sales expected to grow 35% YoY in FY2025. Fundamentals remain solid—maintaining a buy rating. I'll wait for stabilization before adding 10,000 more shares, holding long-term for bigger gains!","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/415801921802584","repostId":0,"isVote":1,"tweetType":1,"viewCount":96,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["00013"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":["晒单贴"],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":408,"optionInvolvedFlag":false,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/415801921802584"}